Regulators gave CoronaVac the green light for mass inoculation, making it the second coronavirus shot in China to get provisional approval. However the Chinese developer of the vaccine: Sinovac Biotech Ltd. has faced questions over its vaccine efficiency due to the lack of transparency around clinical trial data. Latin America, Africa, Asia, and many developing countries have put a lot of their hopes on the CoronaVac. The key distinction in this vaccine compared to the ones produced by the West is that it can be stored in an ordinary refrigerator making it cheaper and easier to transport. However, the drug has produced lower efficacy than originally published dropping from 78% to around 50% during late stage trials in Brazil. Moreover, the Chinese government is donating shots to less affluent countries such as Zimbabwe which will receive 200,000 doses.
It raises the concern of how the United States will respond in competition per say with China. How the Biden administration chooses to approach China's administration of CoronaVac to other countries will be interesting. In the international system, power and your relations with other countries is huge. By China leveraging their power with the CoronaVac vaccination they could be an even greater threat to the United States. Also, it's concerning the lack of information being made public from the Chinese government about this vaccine. Will the United States intervene and help other countries if they purchase the vaccine from Sinovac and issues arise?
-Katie Huey Blog Post #1
Link: https://www.wsj.com/
articles/china-approves-sinovac-vaccine-for-broad-use-against-covid-19-11612617336
No comments:
Post a Comment